You are here: Industry Insights > Biogen

News List

Forward pharma loses Tecfidera patent appeal against Biogen pharmatimes
October 25, 2018
Forward Pharma has lost its appeal on a US Patent Trial and Appeal Board decision that validated patents for Biogen's blockbuster MS drug Tecfidera (dimethyl fumarate).
NICE does not recommend NHS use of Biogen’s nusinersen for SMA pharmaceutical-technology
August 17, 2018
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Biogen’s Spinraza (nusinersen) for routine use by the National Health Service (NHS) to treat spinal muscular atrophy (SMA).
NICE cost watchdogs spurn Biogen's pricey Spinraza but leave door open for a deal fiercepharma
August 15, 2018
Biogen’s spinal muscular atrophy drug Spinraza is picking up steam in the U.S. and beyond, but in the U.K., cost-effectiveness watchdogs have found it too expensive to endorse.
Deals this week: AstraZeneca, Biogen, Midatech Pharma pharmaceutical-technology
July 30, 2018
AstraZeneca has agreed to sell the European commercial rights of its Atacand and Atacand Plus drugs to Cheplapharm Arzneimittel.
Biogen pays $27.5M upfront for 2 AliveGen muscle drugs fiercebiotech
July 26, 2018
Biogen has bolted on a couple of early-stage drug candidates for neuromuscular diseases via a $535 million deal with California startup AliveGen.
Biogen's Spinraza zooms through blockbusterland, but analysts are fixated on Alzheimer's data fiercepharma
July 25, 2018
Biogen's Spinraza took a 100% leap and its multiple sclerosis franchise mostly held its own in the second quarter, but analysts weren't much interested in those topics on Tuesday morning's earnings call.
Eisai and Biogen to move forward with Alzheimer’s drug expressbpd
July 25, 2018
Eisai and Biogen will move forward with late-stage clinical trials of their Alzheimer’s disease drug, BAN2401.
Biogen buys Pfizer’s schizophrenia drug pharmatimes
July 24, 2018
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
Biogen, Samsung Bioepis and Abbvie settle patent dispute pharmatimes
July 18, 2018
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
Biogen’s Alzheimer’s drug succeeds in trial biospectrumasia
July 09, 2018
The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page